Company · HIMS
Hims & Hers Health, Inc.
Nasdaq's symbol directory lists HIMS on the New York Stock Exchange as “Hims & Hers Health, Inc. Class A Common Stock”.
In the 12 months to Nov 19, 2026: insiders sold on 26 occasions ($10.3M); 12 planned-sale notices; 5 filings by holders of 5% or more; 1 congressional trade disclosure; 3 company reports (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Oluyemi Okupe, Chief Financial Officer sold $4.8M
- Soleil Boughton, Chief Legal Officer sold $1.3M
- Mohamed Elshenawy, CTO sold $1.2M
- Autor Deborah M., Chief Policy Officer sold $909K
- Chi Michael, Chief Operating Officer sold $840K
- Carroll Patrick Harrison, Chief Medical Officer sold $830K
- Becklund Irene, PAO sold $371K
Every trade (26)
- SELLAutor Deborah M., Chief Policy Officer sold $442K
- SELLOluyemi Okupe, Chief Financial Officer sold $65K
- SELLSoleil Boughton, Chief Legal Officer sold $64K
- SELLSoleil Boughton, Chief Legal Officer sold $96K
- SELLSoleil Boughton, Chief Legal Officer sold $101K
- SELLOluyemi Okupe, Chief Financial Officer sold $59K
- SELLSoleil Boughton, Chief Legal Officer sold $101K
- SELLOluyemi Okupe, Chief Financial Officer sold $877K
- SELLOluyemi Okupe, Chief Financial Officer sold $355K
- SELLSoleil Boughton, Chief Legal Officer sold $174K
- SELLChi Michael, Chief Operating Officer sold $398K
- SELLMohamed Elshenawy, CTO sold $226K
- SELLSoleil Boughton, Chief Legal Officer sold $98K
- SELLSoleil Boughton, Chief Legal Officer sold $692K
- SELLOluyemi Okupe, Chief Financial Officer sold $148K
- SELLAutor Deborah M., Chief Policy Officer sold $467K
- SELLOluyemi Okupe, Chief Financial Officer sold $262K
- SELLOluyemi Okupe, Chief Financial Officer sold $229K
- SELLOluyemi Okupe, Chief Financial Officer sold $261K
- SELLOluyemi Okupe, Chief Financial Officer sold $619K
- SELLOluyemi Okupe, Chief Financial Officer sold $1.9M
- SELLCarroll Patrick Harrison, Chief Medical Officer sold $830K
- SELLMohamed Elshenawy, CTO sold $946K
- SELLChi Michael, Chief Operating Officer sold $442K
- SELLBecklund Irene, PAO sold $141K
- SELLBecklund Irene, PAO sold $229K
Planned sales · SEC Form 144
Notice given
A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice
- Autor Deborah M. $442K
- Okupe Oluyemi $65K
- Boughton Soleil $64K
- Boughton Soleil $96K
- Boughton Soleil $101K
- Okupe Oluyemi $59K
- Boughton Soleil $101K
- Okupe Oluyemi $877K
- Okupe Oluyemi $355K
- Boughton Soleil $174K
- Chi Michael $398K
- Elshenawy Mohamed $226K
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- G1 Execution Services, LLC 4.8%
- Vanguard Capital Management 4.97%
- Andrew Dudum 9.4%
- Vanguard Capital Management 5.01%
- BlackRock, Inc. 11.9%
Congress · STOCK Act
The Althing
Periodic transaction reports. Amounts are the ranges members report; the trade date is when it happened, the report can come up to 45 days later.
- Tony Wied (R-WI08): Purchase $50,001 - $100,000
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Departure or appointment of directors or officers Nov 9, 2026
- Results of operations and financial condition; Other events Nov 9, 2026
- Departure or appointment of directors or officers Oct 7, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.